About Nesai

We turn facial ultrasound into an objective reading of the skin. AI analyzes the image in real time: where an ultrasound scanner sees the surface, we see the internal structure.

20 years of clinical experience turned into an AI model

Nesai started in Barcelona in 2024 so that the assessment before a treatment no longer relies only on the professional's eye. It wasn't born in a software lab but in two decades of clinical practice: Dr. Francisco de Cabo and Dra. Isabel Bové have spent twenty years applying ultrasound to aesthetic medicine, and that knowledge is what our model turns into a report.

Dr. Francisco de Cabo

Dr. Francisco de Cabo

Co-founder, radiologist

A pioneer in the use of ultrasound in aesthetic medicine, dermatology and plastic surgery for two decades, having compiled more than 400,000 facial images. During the pandemic, that accumulated knowledge became the foundation on which Nesai's AI model was trained.

Dra. Isabel Bové

Dra. Isabel Bové

Co-founder, business development

Medical director and consultant in aesthetic medicine, with 25 years of professional and teaching experience. A pioneer, lecturer and speaker on the applications of aesthetic ultrasound and treatments. Business Development Advisor and co-founder of Nesai. Specialist in Family and Community Medicine and in Emergency Medicine, with a master's degree in Healthcare Management.

David Campos

David Campos

Co-founder and CEO

Telecommunications engineer and expert in organisational development. A leading figure in health tech startups, specialised in turning technological innovation into real solutions and in leading multidisciplinary teams.

Healthcare professional reviewing the Nesai ultrasound report with a patient in the clinic

Who backs us

We're supported by the Microsoft and AWS startup programs, by investors such as Mindsight Ventures, and by public funding from ENISA and the EU's NextGenerationEU funds.

  • Microsoft for Startups
  • AWS Startup Programs
  • Mindsight Ventures
  • DCbehind
  • Farside Advanced Ventures
  • Instituts Guirado

Talk to the team

Clinics that already trust us

Clinics across Spain and laboratories already work with Nesai.

Clínica LunikHospital Clínica FontanaGavín DermatólogosClínica Dr. Morales RayaClínica De Cabo-BovéClínica Dra. Iratxe Díaz - BilbaoAesophy Excellence ClinicClínica Violeta RodríguezClínica Ofelia CasanuevaInstituto de Benito - MadridClínica MayolClínica JovellanosDra Virginia Benítez ClinicClínica Marta SuárezRIBÉ ClinicClínica DabosClínica TufetDoctora BarrigaPB ClinicalInstituto Natividad CanoClínicas Dr. Mercado - MadridDra Marisa ManzanoCastellar ClinicInout BarcelonaClínica Dra. CarideQuiroderma - Centro 2 (Sant Quirze)Clínica Doctora PáezDEMYAMEDISANSClínica Carmen Sarmiento

Nesai at industry congresses

At TechAiDerm, SELMQ and Allergan Aesthetics' A3 event, ultrasound with Nesai was presented as a method for measuring skin quality.

Nesai's stand at the TechAiDerm 2026 congress
TechAiDerm 2026
Dra. Marta Vilavella presenting Nesai as an innovation in dermo-aesthetics at TechAiDerm 2026
TechAiDerm 2026, Dra. Marta Vilavella
Dr. Francisco de Cabo with Dra. Sofía Ruiz del Cueto at TechAiDerm 2026
TechAiDerm 2026, Dr. Francisco de Cabo with Dra. Sofía Ruiz del Cueto
Dra. Isabel Bové presenting at the SELMQ 2026 congress
SELMQ 2026, Dra. Isabel Bové
Dra. Ofelia Casanueva presenting results with Nesai at Allergan Aesthetics' A3 event 2026
A3 Allergan Aesthetics 2026, Dra. Ofelia Casanueva
Dr. Carlos Morales mentioning Nesai at Allergan Aesthetics' A3 event 2026
A3 Allergan Aesthetics 2026, Dr. Carlos Morales
Dra. Isabel Bové with SEME president Dr. Juan Antonio López-Pitalúa at TechAiDerm 2026
TechAiDerm 2026, Dra. Bové with the SEME president
Dr. Francisco de Cabo with Dr. Carlos Morales Raya at TechAiDerm 2026
TechAiDerm 2026, Dr. de Cabo with Dr. Morales Raya
Dr. Fernando Urdiales at Allergan Aesthetics' A3 event 2026
A3 Allergan Aesthetics 2026, Dr. Fernando Urdiales

What others say

See press

Nesai's commitment

Nesai supports clinical judgment; it doesn't replace it. The report gives you objective data, and the decision to treat is always yours. That principle applies to everything the platform produces, without exception.